The advancement of delicate CTC and cfDNA identification led to innovations that has empowered the improvement of liquid biopsies with numerous clinical applications, including-screening for nearness of disease, patient stratification and treatment determination, monitoring treatment reaction and early diagnostics.
MarketsandMarkets Virtual Conference on Liquid Biopsy will unite the pioneers from Diagnostics organization, Experts from Pharmaceutical and Bio-Pharma companies, Researchers and professors from renowned universities to address the challenges in early detection of tumor cells and the potential of liquid biopsies to screen, monitor and treatment of the diseases.
Medical Director, Clinical Asst. Professor of Medicine, Tufts University School of Medicine, Lahey Hospitals and Medical Center
Senior Scientific Project Manager, Cancer Foundation for the National Institutes of Health
Reader in Biomedical Sciences, Brunel University
VP Business Development, Inivata
Director of the Laboratory Rare Circulating Human Cells (LCCRH), l’Université et CHU de Montpellier, France, Europe
Surgical Oncologist, Queens Hospital Cancer Center
Clinical researcher, Oncologist, Fortis Hospital
Professor Department of Biochemistry and Molecular Biology, Beijing Normal University
Team Lead Liquid Biopsy Biobank, Indivumed
Director, Program for Neuroproteomics and Biomarkers Research, University of Florida
Vice Chair- Diagnostic Technology Innovation, Director-Cytopathology, Director-International Telepathology Dept. Pathology and Lab Med, UCLA, David Geffen School of Medicine
